ABCL · NASDAQ · STOCK
AbCellera Biologics (ABCL) Stock Analysis
$12.54
52W $2.75 – $15.02
65/100
$3.83B
-23.2
1.19
Is ABCL Bullish or Bearish?
Bullish.
Innellis AI committee rates AbCellera Biologics Inc. (ABCL) Buy with a composite score of 65/100
, based on 6 analysts with 83% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +9.95 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -10.05 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 101.3% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 30.6% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
65/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 5%
of 192 Healthcare peers
Value Analyst
bullish
60
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.1x is a discount to asset value
− ROE of only -17.5% -- cheap may mean cheap for a reason
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 101.3% YoY -- genuine top-line momentum
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 30.6% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 65.2 to 65.0.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
43.2
Neutral
MACD Histogram
-0.239
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.41
Inside Bands
Price vs Moving Averages
EMA 9
$12.99
Below
EMA 21
$12.71
Below
EMA 50
$11.30
Above
EMA 200
$7.41
Above
Fundamental Analysis
Valuation
52
Growth
78
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-23.2×
P/B Ratio
4.28×
PEG Ratio
42.77
Dividend Yield
0.00%
52W High
$15.02
52W Low
$2.75
Quality & Growth
ROE
-1514.2%
ROA
-1079.0%
Gross Margin
7495.2%
Operating Margin
-34025.4%
Revenue Growth YoY
—
Debt / Equity
0.15
AI Fundamental Assessment
P/E ratio of -23.2 (inexpensive relative to a 15-40x range); Price-to-book of 4.3x; PEG ratio of 42.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -15.1%; Return on assets of -10.8%; Net margin of -248.8%; Gross margin of 75.0%; Current ratio of 12.77 (healthy short-term liquidity); Debt-to-equity of 0.15; Free cash flow per share is negative (-0.59); Most recent quarter missed estimates by 23.5%; EPS growth accelerating (-366.7% -> -28.6% QoQ); Analyst estimates rising over recent quarters
Get the Full ABCL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →